关键数据
0.880今开
0.880最高
15.46K成交量
0.72市盈率 TTM
亏损市盈率动
--股息TTM
0.03%换手率
0.860昨收
0.860最低
6.62K成交额
亏损市盈率静
1.73市净率
0.00%股息率 TTM
-46.30%ROA
2.64052周最高
3.40量比
-53.95M净利润
44.21M总股本
1.2170每股收益TTM
0.79Beta
-775.14%ROE
0.50052周最低
2.34%振幅
57.87%毛利率
38.91M总市值
-1.87回报/风险
5.06%风险率
最新
电话会议纪要

即将为您带来更多新闻,敬请期待。。。
Elutia Inc评分
0.23与上次评分对比预测8.00
财务诊断7.51
技术分析4.63
公司估值9.71
机构认同度3.00
风险评估3.77
分析师评级
买入评级
5.000目标均价
+514.25%涨幅空间
Elutia Inc 最新财报电话会记录
ELUT 2026财年第二季度业绩电话会议: NXT 41X时间线、融资及利润率扩张
ELUT 2026年第二季度销售额降至240万美元,但利润率有所改善。管理层阐述了NXT 41X的FDA时间表、上市计划以及至少可维持至2028年的资金保障。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Elutia Inc 简介
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
行业药品
公司代码ELUT
员工数量51
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| Highcape Partners, L.P. | 11.26% |
|---|
| Nantahala Capital Management, LLC | 7.20% |
|---|
| SilverArc Capital Management, LLC | 6.22% |
|---|
| AIGH Capital Management, LLC. | 6.00% |
|---|
| 股东类型 | 占比 |
|---|
| Private Equity | 17.26% |
|---|
| Hedge Fund | 16.99% |
|---|
| Investment Advisor | 11.40% |
|---|
| Investment Advisor/Hedge Fund | 3.46% |
|---|
常见问题
Elutia Inc(ELUT)的当前股价是多少?
Elutia Inc(ELUT)的当前股价是 0.86。
Elutia Inc股票的52周最高点是2.64。
Elutia Inc股票的52周最低点是0.50。
现在Elutia Inc(ELUT)的股票是买入、持有还是卖出?
根据分析师评级,Elutia Inc(ELUT)的总体评级为买入,目标价格为5.00。
Elutia Inc(ELUT)股票的每股收益(EPS TTM)是多少
Elutia Inc(ELUT)股票的每股收益(EPS TTM)是1.22。